Listed

Praxis Precision Medicines, Inc.

PRAXNasdaqCIK 1689548HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2025
Operating income−$96.9m, Q2 FY2026
Net income−$83.7m, Q2 FY2026
Praxis Precision Medicines, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.5Revenue, Q3 FY2023, three months to 2023-09-30$468.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figure0.5Revenue, Q4 FY2023, three months to 2023-12-31$515.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure0.4Revenue, Q1 FY2024, three months to 2024-03-31$431.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure0.4Revenue, Q2 FY2024, three months to 2024-06-30$357.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure0.3Revenue, Q3 FY2024, three months to 2024-09-30$302.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure7.5Revenue, Q4 FY2024, three months to 2024-12-31$7.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Research and development$m17.3Research and development, Q3 FY2023, three months to 2023-09-30$17.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figure18.4Research and development, Q4 FY2023, three months to 2023-12-31$18.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure27.0Research and development, Q1 FY2024, three months to 2024-03-31$27.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure27.3Research and development, Q2 FY2024, three months to 2024-06-30$27.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure41.9Research and development, Q3 FY2024, three months to 2024-09-30$41.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure56.3Research and development, Q4 FY2024, three months to 2024-12-31$56.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure60.8Research and development, Q1 FY2025, three months to 2025-03-31$60.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure63.0Research and development, Q2 FY2025, three months to 2025-06-30$63.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure65.8Research and development, Q3 FY2025, three months to 2025-09-30$65.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure77.5Research and development, Q4 FY2025, three months to 2025-12-31$77.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure78.0Research and development, Q1 FY2026, three months to 2026-03-31$78.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure69.4Research and development, Q2 FY2026, three months to 2026-06-30$69.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Operating income$m(25.5)Operating income, Q3 FY2023, three months to 2023-09-30−$25.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figure(27.8)Operating income, Q4 FY2023, three months to 2023-12-31−$27.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure(41.9)Operating income, Q1 FY2024, three months to 2024-03-31−$41.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure(37.5)Operating income, Q2 FY2024, three months to 2024-06-30−$37.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure(56.8)Operating income, Q3 FY2024, three months to 2024-09-30−$56.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure(64.0)Operating income, Q4 FY2024, three months to 2024-12-31−$64.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure(74.7)Operating income, Q1 FY2025, three months to 2025-03-31−$74.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(76.1)Operating income, Q2 FY2025, three months to 2025-06-30−$76.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure(78.4)Operating income, Q3 FY2025, three months to 2025-09-30−$78.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure(97.0)Operating income, Q4 FY2025, three months to 2025-12-31−$97.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure(106)Operating income, Q1 FY2026, three months to 2026-03-31−$105.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(96.9)Operating income, Q2 FY2026, three months to 2026-06-30−$96.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(24.6)Net income, Q3 FY2023, three months to 2023-09-30−$24.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0001689548-25-000040.Report this figure(26.9)Net income, Q4 FY2023, three months to 2023-12-31−$26.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0001689548-25-000040.Report this figure(39.6)Net income, Q1 FY2024, three months to 2024-03-31−$39.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure(32.7)Net income, Q2 FY2024, three months to 2024-06-30−$32.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure(51.9)Net income, Q3 FY2024, three months to 2024-09-30−$51.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure(58.7)Net income, Q4 FY2024, three months to 2024-12-31−$58.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0001689548-25-000040.Report this figure(69.3)Net income, Q1 FY2025, three months to 2025-03-31−$69.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure(71.1)Net income, Q2 FY2025, three months to 2025-06-30−$71.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure(73.9)Net income, Q3 FY2025, three months to 2025-09-30−$73.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure(88.9)Net income, Q4 FY2025, three months to 2025-12-31−$88.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure(92.6)Net income, Q1 FY2026, three months to 2026-03-31−$92.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure(83.7)Net income, Q2 FY2026, three months to 2026-06-30−$83.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Diluted EPS$ per share(2.72)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$2.72 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figurenot reported(2.84)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$2.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure(1.74)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure(2.75)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$2.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figurenot reported(3.29)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$3.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(3.31)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$3.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure(3.36)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$3.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figurenot reported(3.20)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$3.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(2.87)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Basic EPS$ per share(2.72)Basic EPS, Q3 FY2023, three months to 2023-09-30−$2.72 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figurenot reported(2.84)Basic EPS, Q1 FY2024, three months to 2024-03-31−$2.84 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure(1.74)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1.74 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure(2.75)Basic EPS, Q3 FY2024, three months to 2024-09-30−$2.75 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figurenot reported(3.29)Basic EPS, Q1 FY2025, three months to 2025-03-31−$3.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(3.31)Basic EPS, Q2 FY2025, three months to 2025-06-30−$3.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure(3.36)Basic EPS, Q3 FY2025, three months to 2025-09-30−$3.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figurenot reported(3.20)Basic EPS, Q1 FY2026, three months to 2026-03-31−$3.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(2.87)Basic EPS, Q2 FY2026, three months to 2026-06-30−$2.87 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure

Balance sheet

Cash and equivalents$474.8m, Q2 FY2026
Shareholders' equity$1.34bn, Q2 FY2026
Praxis Precision Medicines, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m101Cash and equivalents, Q3 FY2023, at 2023-09-30$101.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figure81.3Cash and equivalents, FY2023, at 2023-12-31$81.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure152Cash and equivalents, Q1 FY2024, at 2024-03-31$152.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure145Cash and equivalents, Q2 FY2024, at 2024-06-30$145.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure169Cash and equivalents, Q3 FY2024, at 2024-09-30$168.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure215Cash and equivalents, FY2024, at 2024-12-31$215.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure166Cash and equivalents, Q1 FY2025, at 2025-03-31$165.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure157Cash and equivalents, Q2 FY2025, at 2025-06-30$157.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure150Cash and equivalents, Q3 FY2025, at 2025-09-30$149.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure357Cash and equivalents, FY2025, at 2025-12-31$357.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure536Cash and equivalents, Q1 FY2026, at 2026-03-31$536.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure475Cash and equivalents, Q2 FY2026, at 2026-06-30$474.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Current assets$m103Current assets, Q3 FY2023, at 2023-09-30$103.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-07, accession 0001689548-23-000159.Report this figure84.9Current assets, FY2023, at 2023-12-31$84.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-28, accession 0001689548-25-000040.Report this figure212Current assets, Q1 FY2024, at 2024-03-31$211.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-13, accession 0001689548-24-000060.Report this figure357Current assets, Q2 FY2024, at 2024-06-30$356.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001689548-24-000088.Report this figure360Current assets, Q3 FY2024, at 2024-09-30$360.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figure404Current assets, FY2024, at 2024-12-31$404.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure334Current assets, Q1 FY2025, at 2025-03-31$333.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure307Current assets, Q2 FY2025, at 2025-06-30$306.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure274Current assets, Q3 FY2025, at 2025-09-30$273.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure611Current assets, FY2025, at 2025-12-31$610.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure798Current assets, Q1 FY2026, at 2026-03-31$797.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure772Current assets, Q2 FY2026, at 2026-06-30$771.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Total assets$m107Total assets, Q3 FY2023, at 2023-09-30$106.7m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-07, accession 0001689548-23-000159.Report this figure87.9Total assets, FY2023, at 2023-12-31$87.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-28, accession 0001689548-25-000040.Report this figure250Total assets, Q1 FY2024, at 2024-03-31$250.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-13, accession 0001689548-24-000060.Report this figure441Total assets, Q2 FY2024, at 2024-06-30$441.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001689548-24-000088.Report this figure416Total assets, Q3 FY2024, at 2024-09-30$416.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figure483Total assets, FY2024, at 2024-12-31$483.1m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure479Total assets, Q1 FY2025, at 2025-03-31$478.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure453Total assets, Q2 FY2025, at 2025-06-30$452.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure396Total assets, Q3 FY2025, at 2025-09-30$396.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure938Total assets, FY2025, at 2025-12-31$937.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure1,460Total assets, Q1 FY2026, at 2026-03-31$1.46bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure1,390Total assets, Q2 FY2026, at 2026-06-30$1.39bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Current liabilities$m16.8Current liabilities, Q3 FY2023, at 2023-09-30$16.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-07, accession 0001689548-23-000159.Report this figure15.7Current liabilities, FY2023, at 2023-12-31$15.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-28, accession 0001689548-25-000040.Report this figure18.8Current liabilities, Q1 FY2024, at 2024-03-31$18.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-13, accession 0001689548-24-000060.Report this figure20.6Current liabilities, Q2 FY2024, at 2024-06-30$20.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001689548-24-000088.Report this figure32.9Current liabilities, Q3 FY2024, at 2024-09-30$32.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figure37.6Current liabilities, FY2024, at 2024-12-31$37.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure39.5Current liabilities, Q1 FY2025, at 2025-03-31$39.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure48.6Current liabilities, Q2 FY2025, at 2025-06-30$48.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure52.9Current liabilities, Q3 FY2025, at 2025-09-30$52.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure59.8Current liabilities, FY2025, at 2025-12-31$59.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure50.2Current liabilities, Q1 FY2026, at 2026-03-31$50.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure49.1Current liabilities, Q2 FY2026, at 2026-06-30$49.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Total liabilities$m20.0Total liabilities, Q3 FY2023, at 2023-09-30$20.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-07, accession 0001689548-23-000159.Report this figure18.3Total liabilities, FY2023, at 2023-12-31$18.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-28, accession 0001689548-25-000040.Report this figure20.7Total liabilities, Q1 FY2024, at 2024-03-31$20.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-13, accession 0001689548-24-000060.Report this figure22.0Total liabilities, Q2 FY2024, at 2024-06-30$22.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001689548-24-000088.Report this figure33.6Total liabilities, Q3 FY2024, at 2024-09-30$33.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figure37.7Total liabilities, FY2024, at 2024-12-31$37.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure39.5Total liabilities, Q1 FY2025, at 2025-03-31$39.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure48.6Total liabilities, Q2 FY2025, at 2025-06-30$48.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure52.9Total liabilities, Q3 FY2025, at 2025-09-30$52.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure59.8Total liabilities, FY2025, at 2025-12-31$59.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure50.2Total liabilities, Q1 FY2026, at 2026-03-31$50.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure49.1Total liabilities, Q2 FY2026, at 2026-06-30$49.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Shareholders' equity$m86.8Shareholders' equity, Q3 FY2023, at 2023-09-30$86.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2025-02-28, accession 0001689548-25-000040.Report this figure69.7Shareholders' equity, FY2023, at 2023-12-31$69.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure230Shareholders' equity, Q1 FY2024, at 2024-03-31$229.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure419Shareholders' equity, Q2 FY2024, at 2024-06-30$419.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure383Shareholders' equity, Q3 FY2024, at 2024-09-30$382.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure445Shareholders' equity, FY2024, at 2024-12-31$445.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure439Shareholders' equity, Q1 FY2025, at 2025-03-31$439.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure404Shareholders' equity, Q2 FY2025, at 2025-06-30$404.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure344Shareholders' equity, Q3 FY2025, at 2025-09-30$343.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure878Shareholders' equity, FY2025, at 2025-12-31$878.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure1,410Shareholders' equity, Q1 FY2026, at 2026-03-31$1.41bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure1,341Shareholders' equity, Q2 FY2026, at 2026-06-30$1.34bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure

Cash flow

Operating cash flow−$77.5m, Q2 FY2026
Capital expenditure$245.0k, Q2 FY2026
Praxis Precision Medicines, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(23.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$23.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-06, accession 0001689548-24-000101. Derived: 9-month figure less the 6-month figure.Report this figure(23.9)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$23.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure(20.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$20.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure(27.3)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$27.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-04, accession 0001689548-25-000092. Derived: 6-month figure less the 3-month figure.Report this figure(27.5)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$27.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001689548-25-000111. Derived: 9-month figure less the 6-month figure.Report this figure(56.1)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$56.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure(53.0)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$53.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(54.7)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$54.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure(65.1)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$65.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001689548-25-000111. Derived: 9-month figure less the 6-month figure.Report this figure(76.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$76.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure(86.2)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$86.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(77.5)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$77.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2023-11-07, accession 0001689548-23-000159. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2023, three months to 2023-12-31$50.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001689548-25-000111. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$56.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001689548-25-000111. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$62.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure0.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$245.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)29.13m, Q2 FY2026
Praxis Precision Medicines, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares45.8Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3045,774,376 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-07, accession 0001689548-23-000159.Report this figure3.5Diluted shares (weighted), Q1 FY2023, three months to 2023-03-313,540,185 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-13, accession 0001689548-24-000060.Report this figure4.6Diluted shares (weighted), Q2 FY2023, three months to 2023-06-304,649,371 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001689548-24-000088.Report this figure9.0Diluted shares (weighted), Q3 FY2023, three months to 2023-09-309,039,427 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-06, accession 0001689548-24-000101.Report this figure13.9Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3113,904,374 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure18.8Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3018,824,479 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure18.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3018,884,562 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure21.1Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3121,055,834 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure21.5Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3021,474,827 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure22.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3021,977,268 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure28.9Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3128,883,596 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure29.1Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3029,131,375 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure

Shares outstanding: 27.92mShares outstanding, period not labelled, at 2026-07-3127,919,988 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.